PE20100317A1 - Antagonistas de heteroarilo de receptores de prostaglandina d2 - Google Patents

Antagonistas de heteroarilo de receptores de prostaglandina d2

Info

Publication number
PE20100317A1
PE20100317A1 PE2009001158A PE2009001158A PE20100317A1 PE 20100317 A1 PE20100317 A1 PE 20100317A1 PE 2009001158 A PE2009001158 A PE 2009001158A PE 2009001158 A PE2009001158 A PE 2009001158A PE 20100317 A1 PE20100317 A1 PE 20100317A1
Authority
PE
Peru
Prior art keywords
pyridin
amino
alkyl
methyl
prostaglandin
Prior art date
Application number
PE2009001158A
Other languages
English (en)
Spanish (es)
Inventor
John Howard Hutchinson
Brian Andrew Stearns
Nicholas Simon Stock
Yen Pham Truong
Jeffrey Roger Roppe
Deborah Volkots
Jill Melissa Scott
Timothy Parr
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of PE20100317A1 publication Critical patent/PE20100317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2009001158A 2008-09-29 2009-09-28 Antagonistas de heteroarilo de receptores de prostaglandina d2 PE20100317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10107408P 2008-09-29 2008-09-29

Publications (1)

Publication Number Publication Date
PE20100317A1 true PE20100317A1 (es) 2010-05-18

Family

ID=41327552

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001158A PE20100317A1 (es) 2008-09-29 2009-09-28 Antagonistas de heteroarilo de receptores de prostaglandina d2

Country Status (11)

Country Link
US (2) US20110312974A1 (enExample)
EP (1) EP2328869A4 (enExample)
JP (1) JP2012504141A (enExample)
CN (1) CN102164894A (enExample)
AR (1) AR073319A1 (enExample)
CA (1) CA2737739C (enExample)
GB (1) GB2463788B (enExample)
PE (1) PE20100317A1 (enExample)
TW (1) TW201018465A (enExample)
UY (1) UY32152A (enExample)
WO (2) WO2010037054A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
US20110098352A1 (en) * 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US8242145B2 (en) * 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2268611A2 (en) * 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US8710163B2 (en) 2008-07-25 2014-04-29 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US8674040B2 (en) 2008-07-25 2014-03-18 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
KR20120046762A (ko) * 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 피부 제형
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
US8835563B2 (en) 2011-03-25 2014-09-16 Exxonmobil Chemical Patents Inc. Block copolymers from silylated vinyl terminated macromers
US8318998B2 (en) 2011-03-25 2012-11-27 Exxonmobil Chemical Patents Inc. Enhanced catalyst performance for production of vinyl terminated propylene and ethylene/propylene macromers
US8623974B2 (en) 2011-03-25 2014-01-07 Exxonmobil Chemical Patents Inc. Branched vinyl terminated polymers and methods for production thereof
US8399724B2 (en) 2011-03-25 2013-03-19 Exxonmobil Chemical Patents Inc. Vinyl terminated higher olefin copolymers and methods to produce thereof
US8841397B2 (en) 2011-03-25 2014-09-23 Exxonmobil Chemical Patents Inc. Vinyl terminated higher olefin polymers and methods to produce thereof
US8940839B2 (en) 2011-03-25 2015-01-27 Exxonmobil Chemical Patents Inc. Diblock copolymers prepared by cross metathesis
JP5820056B2 (ja) 2011-04-12 2015-11-24 チョン クン ダン ファーマシューティカル コーポレーション Ｃｅｔｐ阻害剤としてのシクロアルケニルアリール誘導体
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
US9102773B2 (en) 2013-02-06 2015-08-11 Exxonmobil Chemical Patents Inc. Process for controlling molecular weight of polyolefins prepared using pyridyl diamide catalyst systems
US9290519B2 (en) 2013-11-15 2016-03-22 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US9260552B2 (en) 2013-11-15 2016-02-16 Exxonmobil Chemical Patents Inc. Process to produce polymers from pyridyldiamido transition metal complexes and use thereof
US9315593B2 (en) 2013-11-15 2016-04-19 Exxonmobil Chemical Patents Inc. Catalyst systems comprising pyridyldiamido transition metal complexes and chain transfer agent and use thereof
WO2015073157A1 (en) 2013-11-15 2015-05-21 Exxonmobil Chemical Patents Inc. Process to produce polymers from pyridyldiamido transition metal complexes and use thereof
US9315526B2 (en) 2014-03-03 2016-04-19 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US9598444B2 (en) 2015-06-30 2017-03-21 Exxonmobil Chemical Patents Inc. Transition metal complexes of tridentate dianionic CNN ligands, production and use thereof
EP3317288A4 (en) 2015-06-30 2019-03-13 ExxonMobil Chemical Patents Inc. TRANSITION METAL COMPLEXES OF TRIDENTATE DIANIONIC CNN LIGANDS, MANUFACTURE AND USE THEREOF
BR112018001809A2 (pt) * 2015-08-17 2018-09-18 Japan Tobacco, Inc. composto de hidroxitriazina e uso médico do mesmo
US10618988B2 (en) 2015-08-31 2020-04-14 Exxonmobil Chemical Patents Inc. Branched propylene polymers produced via use of vinyl transfer agents and processes for production thereof
KR102081523B1 (ko) 2015-08-31 2020-02-25 엑손모빌 케미칼 패턴츠 인코포레이티드 비닐 이동제의 사용을 통해 제조된 중합체
WO2017039995A1 (en) 2015-08-31 2017-03-09 Exxonmobil Chemical Patents Inc. Aluminum alkyls with pendant olefins for polyolefin reactions
EP3344385A4 (en) 2015-08-31 2019-08-14 ExxonMobil Chemical Patents Inc. ALUMINUM ALKYLE WITH HANGING OLEFINS ON SOUND
US9982067B2 (en) 2015-09-24 2018-05-29 Exxonmobil Chemical Patents Inc. Polymerization process using pyridyldiamido compounds supported on organoaluminum treated layered silicate supports
US10562987B2 (en) 2016-06-30 2020-02-18 Exxonmobil Chemical Patents Inc. Polymers produced via use of quinolinyldiamido transition metal complexes and vinyl transfer agents
SG11201811335UA (en) 2016-06-30 2019-01-30 Exxonmobil Chemical Patents Inc Quinolinyldiamido transition metal complexes, production and use thereof
US10208140B2 (en) 2016-06-30 2019-02-19 Exxonmobil Chemical Patents Inc. Quinolinyldiamido transition metal complexes, production and use thereof
US10927196B2 (en) 2016-06-30 2021-02-23 Exxonmobil Chemical Patents Inc. Long chain branched polypropylene via polymerization with aluminum vinyl transfer agent
WO2018022249A1 (en) 2016-07-29 2018-02-01 Exxonmobil Chemical Patents Inc. Heterocyclic amido transition metal complexes, production and use thereof
US10150821B2 (en) 2016-07-29 2018-12-11 Exxonmobil Chemical Patents Inc. Heterocyclic amido transition metal complexes, production and use thereof
US10882932B2 (en) 2016-10-05 2021-01-05 Exxonmobil Chemical Patents Inc. Sterically hindered metallocenes, synthesis and use
US10626200B2 (en) 2017-02-28 2020-04-21 Exxonmobil Chemical Patents Inc. Branched EPDM polymers produced via use of vinyl transfer agents and processes for production thereof
US10676551B2 (en) 2017-03-01 2020-06-09 Exxonmobil Chemical Patents Inc. Branched ethylene copolymers produced via use of vinyl transfer agents and processes for production thereof
CN109485664B (zh) * 2017-09-12 2022-03-08 北京凯莱天成医药科技有限公司 一种抗真菌药物他伐硼罗的制备工艺
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11479625B2 (en) 2018-03-08 2022-10-25 Exxonmobil Chemical Patents Inc. Ethylene-propylene branched copolymers as viscosity modifiers with enhanced fuel economy
US11578155B2 (en) 2018-03-08 2023-02-14 Exxonmobil Chemical Patents Inc. Ethylene-propylene linear copolymers as viscosity modifiers
CN109266735A (zh) * 2018-06-15 2019-01-25 天津医科大学 Crth2作为肺动脉高压免疫治疗药物靶标及其应用
US20220289882A1 (en) 2019-08-27 2022-09-15 Chevron Oronite Company Llc Ethylene copolymers and use as viscosity modifiers
CN110878043B (zh) * 2019-11-18 2020-08-14 南京哈柏医药科技有限公司 一种地平类降压药物中间体6-甲氧基吡啶-3-甲醛的合成方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US5827868A (en) 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
US5565485A (en) 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
DE19601782A1 (de) 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
DE19937537A1 (de) 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
CA2383135C (en) 1999-08-23 2010-11-30 Hiroyuki Hirai Method of identifying properties of substance with respect to human prostaglandin d2 receptors
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
CA2452391A1 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
EP1556356B1 (en) 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
AU2003275868B2 (en) 2002-10-30 2009-07-09 Merck Frosst Canada Ltd Pyridopyrrolizine and pyridoindolizine derivatives
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
CA2540640A1 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
WO2005100298A1 (en) * 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
JP2008508306A (ja) 2004-07-30 2008-03-21 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体のインダノン増強剤
BRPI0515522A (pt) 2004-09-21 2008-07-29 Athersys Inc composto, composição farmacêutica. métodos de inibir a ligação de ligandos endógenos ao receptor crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor crth-2 em um animal e de preparar um composto, e, kit
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) 2004-11-08 2007-12-27 Tobert Jonathan A Method of Treating Pathological Blushing
EP1814871B1 (en) * 2004-11-19 2011-03-02 Galderma Research & Development Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions
JP2008520645A (ja) 2004-11-23 2008-06-19 ファイザー・プロダクツ・インク ジベンジルアミン化合物および誘導体
PT1833791E (pt) 2004-12-27 2011-10-19 Actelion Pharmaceuticals Ltd Derivados de 2,3,4,9-tetra-hidro-1h-carbazol como antgonistas do receptor crth2
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
CA2598934A1 (en) * 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
RU2008110949A (ru) 2005-08-23 2009-09-27 Айрм Ллк (Bm) Соединения и композиции-иммуносупрессанты
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
PT2051962E (pt) 2006-08-07 2012-01-10 Actelion Pharmaceuticals Ltd Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
US8183289B2 (en) 2006-08-21 2012-05-22 Array Biopharma Inc. 4-substituted phenoxyphenylacetic acid derivatives
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
US7629258B2 (en) * 2006-11-22 2009-12-08 Clarkson University Method for one-to-one polishing of silicon nitride and silicon oxide
WO2008082567A1 (en) 2006-12-29 2008-07-10 Merck & Co., Inc. Process for synthesizing a cetp inhibitor
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
CN103172572A (zh) 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20100280049A1 (en) 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
EP2240434A1 (en) 2008-01-07 2010-10-20 Ligand Pharmaceuticals Inc. 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders
ES2442717T3 (es) 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
US20110098352A1 (en) 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
BRPI0913930A2 (pt) 2008-07-03 2015-10-20 Amira Pharmaceuticals Inc antagonistas de receptores de prostaglandinas d2
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
KR20120046762A (ko) 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 피부 제형
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途

Also Published As

Publication number Publication date
AR073319A1 (es) 2010-10-28
CA2737739C (en) 2013-09-24
US8049015B2 (en) 2011-11-01
WO2010037054A3 (en) 2010-07-08
WO2010037059A2 (en) 2010-04-01
TW201018465A (en) 2010-05-16
GB2463788A (en) 2010-03-31
WO2010037059A3 (en) 2010-07-22
GB2463788B (en) 2010-12-15
US20110312974A1 (en) 2011-12-22
EP2328869A4 (en) 2013-01-09
JP2012504141A (ja) 2012-02-16
WO2010037054A2 (en) 2010-04-01
GB0916810D0 (en) 2009-11-04
US20100081673A1 (en) 2010-04-01
CA2737739A1 (en) 2010-04-01
UY32152A (es) 2010-04-30
EP2328869A2 (en) 2011-06-08
CN102164894A (zh) 2011-08-24

Similar Documents

Publication Publication Date Title
PE20100317A1 (es) Antagonistas de heteroarilo de receptores de prostaglandina d2
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
PE20211640A1 (es) INHIBICION DE LA INTEGRINA xvß6
PE20051146A1 (es) Compuestos heterociclicos anticitocina
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
PE20130039A1 (es) Pirazoles fungicidas
PE20091930A1 (es) Compuestos de pirazol, procesos para su produccion y herbicidas que los contienen
JP2009541415A5 (enExample)
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
PE20120812A1 (es) Compuestos vinil indazolilo
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20121519A1 (es) Compuestos de pirazol como antagonistas de crth2
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
NZ579833A (en) 7-substituted indole mcl-1 inhibitors
AR054278A1 (es) Formas polimorficas del ester etilico del acido 3-((2-{ (4-(hexiloxicarbonilamino- imino-metil)- fenilamino)-metil} -1-metil-h-bencimidazol-5- carbonil) piridin-2-il-amino)-propionico
CL2009001915A1 (es) Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexilcarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico; util como antitrombotico (divisional de la solicitud cl 425-2003).
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
PE20120997A1 (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico
WO2008136279A1 (ja) ヘテロ環置換ピリジン誘導体の塩またはその結晶
PE20140609A1 (es) Diazacarbazoles y metodos de uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal